ARBITER 2 Trial: Difference between revisions
Rim Halaby (talk | contribs) (Created page with "__NOTOC__ {{High density lipoprotein}} {{CMG}} ==ARBITER 2 Trial== ===Objective=== To assess if treatment with extended release niacin when added to statin monotherap...") |
Rim Halaby (talk | contribs) No edit summary |
||
| Line 3: | Line 3: | ||
{{CMG}} | {{CMG}} | ||
==Objective== | |||
To assess if treatment with extended release [[niacin]] when added to [[statin]] monotherapy slows progression of [[atherosclerosis]] among individuals with known [[coronary artery disease]] ([[CAD]]) and moderately low HDL-C. | To assess if treatment with extended release [[niacin]] when added to [[statin]] monotherapy slows progression of [[atherosclerosis]] among individuals with known [[coronary artery disease]] ([[CAD]]) and moderately low HDL-C. | ||
==Methods== | |||
ARBITER (Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol) 2 was a double blinded randomized placebo controlled study of once daily extended release niacin (1000 mg). 167 patients with known CAD and moderately low HDL-C were enrolled in this study and were assessed for the primary end-point [[carotid intima-media thickness]] (CIMT) at the end of one year. | ARBITER (Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol) 2 was a double blinded randomized placebo controlled study of once daily extended release niacin (1000 mg). 167 patients with known CAD and moderately low HDL-C were enrolled in this study and were assessed for the primary end-point [[carotid intima-media thickness]] (CIMT) at the end of one year. | ||
==Results== | |||
At the end of 12 months mean CIMT significantly increased in the placebo group but not in the niacin group. Niacin significantly reduced the rate of IMT progression in patients without [[insulin resistance]]. Patients treated with niacin had a significant increase in [[HDL]] levels from a mean of 39 mg/dL to 47 mg/dL. Clinical cardiovascular events occurred in 3 patients on niacin and 7 patients treated with placebo. | At the end of 12 months mean CIMT significantly increased in the placebo group but not in the niacin group. Niacin significantly reduced the rate of IMT progression in patients without [[insulin resistance]]. Patients treated with niacin had a significant increase in [[HDL]] levels from a mean of 39 mg/dL to 47 mg/dL. Clinical cardiovascular events occurred in 3 patients on niacin and 7 patients treated with placebo. | ||
==Conclusion== | |||
The addition of extended-release niacin to statin therapy slowed the progression of atherosclerosis among individuals with known coronary heart disease and moderately low HDL-C.<ref name="pmid15537681">{{cite journal |author=Taylor AJ, Sullenberger LE, Lee HJ, Lee JK, Grace KA |title=Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol (ARBITER) 2: a double-blind, placebo-controlled study of extended-release niacin on atherosclerosis progression in secondary prevention patients treated with statins |journal=Circulation |volume=110 |issue=23 |pages=3512–7 |year=2004 |month=December |pmid=15537681 |doi=10.1161/01.CIR.0000148955.19792.8D |url=}}</ref> | The addition of extended-release niacin to statin therapy slowed the progression of atherosclerosis among individuals with known coronary heart disease and moderately low HDL-C.<ref name="pmid15537681">{{cite journal |author=Taylor AJ, Sullenberger LE, Lee HJ, Lee JK, Grace KA |title=Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol (ARBITER) 2: a double-blind, placebo-controlled study of extended-release niacin on atherosclerosis progression in secondary prevention patients treated with statins |journal=Circulation |volume=110 |issue=23 |pages=3512–7 |year=2004 |month=December |pmid=15537681 |doi=10.1161/01.CIR.0000148955.19792.8D |url=}}</ref> | ||
| Line 22: | Line 21: | ||
[[Category:Lipopedia]] | [[Category:Lipopedia]] | ||
[[Category:HDL]] | [[Category:HDL]] | ||
[[Category:Clinical trials]] | |||
Revision as of 23:18, 17 September 2013
|
High Density Lipoprotein Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Clinical Trials |
|
Case Studies |
|
ARBITER 2 Trial On the Web |
|
American Roentgen Ray Society Images of ARBITER 2 Trial |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Objective
To assess if treatment with extended release niacin when added to statin monotherapy slows progression of atherosclerosis among individuals with known coronary artery disease (CAD) and moderately low HDL-C.
Methods
ARBITER (Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol) 2 was a double blinded randomized placebo controlled study of once daily extended release niacin (1000 mg). 167 patients with known CAD and moderately low HDL-C were enrolled in this study and were assessed for the primary end-point carotid intima-media thickness (CIMT) at the end of one year.
Results
At the end of 12 months mean CIMT significantly increased in the placebo group but not in the niacin group. Niacin significantly reduced the rate of IMT progression in patients without insulin resistance. Patients treated with niacin had a significant increase in HDL levels from a mean of 39 mg/dL to 47 mg/dL. Clinical cardiovascular events occurred in 3 patients on niacin and 7 patients treated with placebo.
Conclusion
The addition of extended-release niacin to statin therapy slowed the progression of atherosclerosis among individuals with known coronary heart disease and moderately low HDL-C.[1]
References
- ↑ Taylor AJ, Sullenberger LE, Lee HJ, Lee JK, Grace KA (2004). "Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol (ARBITER) 2: a double-blind, placebo-controlled study of extended-release niacin on atherosclerosis progression in secondary prevention patients treated with statins". Circulation. 110 (23): 3512–7. doi:10.1161/01.CIR.0000148955.19792.8D. PMID 15537681. Unknown parameter
|month=ignored (help)